Avantor (AVTR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of nine director nominees at the annual meeting scheduled for May 7, 2026.
Advisory approval of named executive officer compensation is on the ballot.
Shareholders will vote on the frequency of future advisory votes on executive compensation, with the board recommending an annual (1 year) vote.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 is included.
Other business may be considered if properly brought before the meeting.
Board of directors and corporate governance
Nine individuals are nominated for election to the board, including Simon Dingemans, Emmanuel Ligner, Gregory Lucier, Dame Louise Makin, Joseph Massaro, Sanjeev Mehra, Mala Murthy, Michael Severino, and Gregory Summe.
Executive compensation and say-on-pay
An advisory vote will be held to approve named executive officer compensation.
Shareholders will also vote on how frequently they wish to hold future advisory votes on executive compensation, with a recommendation for every year.
Latest events from Avantor
- Proxy details leadership transitions, Revival strategy, and votes on directors, pay, and auditor.AVTR
Proxy filing27 Mar 2026 - Q3 2025 net loss of $711.8M on 5.3% lower sales; $500M buyback and cost actions announced.AVTR
Q3 202517 Mar 2026 - 2026 is a transition year with Revival investments, margin pressure, and strong free cash flow.AVTR
Q4 202511 Feb 2026 - Q2 2024 saw margin expansion, net income rebound, and reaffirmed full-year guidance.AVTR
Q2 20242 Feb 2026 - Cost transformation and innovation drive margin expansion and resilience amid cautious demand.AVTR
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Cost transformation and bioprocessing momentum support a positive growth outlook.AVTR
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 saw $1.71B revenue, strong cash flow, and raised FCF guidance amid cost transformation.AVTR
Q3 202418 Jan 2026 - Revival program and capital strategy accelerate transformation and global leadership.AVTR
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Bioprocessing and healthcare drive growth, with strong order trends and margin expansion into 2025.AVTR
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026